BRPI0610030B8 - Composto, composição farmacêutica, e, uso de um composto - Google Patents

Composto, composição farmacêutica, e, uso de um composto

Info

Publication number
BRPI0610030B8
BRPI0610030B8 BRPI0610030A BRPI0610030A BRPI0610030B8 BR PI0610030 B8 BRPI0610030 B8 BR PI0610030B8 BR PI0610030 A BRPI0610030 A BR PI0610030A BR PI0610030 A BRPI0610030 A BR PI0610030A BR PI0610030 B8 BRPI0610030 B8 BR PI0610030B8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
hydrogen
optionally substituted
hetero atom
Prior art date
Application number
BRPI0610030A
Other languages
English (en)
Portuguese (pt)
Inventor
Alvin Johns Brian
Takashi Kawasuji
Yoshiyuki Taoda
Teruhiko Taishi
Original Assignee
Glaxosmithkline Llc
Shionogi & Co
Smithline Beecham Corp
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0610030(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc, Shionogi & Co, Smithline Beecham Corp, Viiv Healthcare Co filed Critical Glaxosmithkline Llc
Publication of BRPI0610030A2 publication Critical patent/BRPI0610030A2/pt
Publication of BRPI0610030B1 publication Critical patent/BRPI0610030B1/pt
Publication of BRPI0610030B8 publication Critical patent/BRPI0610030B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0610030A 2005-04-28 2006-04-28 Composto, composição farmacêutica, e, uso de um composto BRPI0610030B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2005-131161 2005-04-28
JP2005131161 2005-04-28
JP2005-312076 2005-10-27
JP2005312076 2005-10-27
PCT/US2006/016604 WO2006116764A1 (en) 2005-04-28 2006-04-28 Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Publications (3)

Publication Number Publication Date
BRPI0610030A2 BRPI0610030A2 (pt) 2011-10-11
BRPI0610030B1 BRPI0610030B1 (pt) 2020-09-15
BRPI0610030B8 true BRPI0610030B8 (pt) 2022-01-11

Family

ID=37215098

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610030A BRPI0610030B8 (pt) 2005-04-28 2006-04-28 Composto, composição farmacêutica, e, uso de um composto

Country Status (30)

Country Link
US (22) US8129385B2 (enExample)
EP (9) EP3045206B2 (enExample)
JP (2) JP4295353B2 (enExample)
KR (4) KR101363875B1 (enExample)
AU (1) AU2006239177B8 (enExample)
BE (1) BE2021C519I2 (enExample)
BR (1) BRPI0610030B8 (enExample)
CA (1) CA2606282C (enExample)
CY (7) CY1115151T1 (enExample)
DK (6) DK3045206T3 (enExample)
EA (1) EA014162B1 (enExample)
ES (7) ES2906792T3 (enExample)
FI (1) FIC20210017I1 (enExample)
FR (1) FR14C0041I2 (enExample)
HK (2) HK1249742A1 (enExample)
HU (6) HUE037795T2 (enExample)
IL (4) IL186555A (enExample)
LT (5) LT3045206T (enExample)
LU (2) LU92446I2 (enExample)
MA (1) MA29460B1 (enExample)
MX (2) MX302718B (enExample)
NL (2) NL300676I2 (enExample)
NO (5) NO339525B1 (enExample)
NZ (1) NZ562339A (enExample)
PL (5) PL3372281T3 (enExample)
PT (5) PT1874117E (enExample)
SI (6) SI3372281T1 (enExample)
TW (1) TWI378931B (enExample)
VN (1) VN34404A1 (enExample)
WO (1) WO2006116764A1 (enExample)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101723949B (zh) 2003-12-24 2013-10-23 生物区科学管理控股有限公司 用于治疗呼吸道合胞体病毒感染的多环试剂
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
SI3372281T1 (sl) * 2005-04-28 2021-11-30 Viiv Healthcare Company Policiklični karbamoilpiridonski derivati, ki imajo aktivnost inhibitorja HIV integraze
EP1881825B1 (en) 2005-05-10 2013-07-24 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
AU2006299042B8 (en) 2005-10-04 2011-09-15 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa HIV integrase inhibitors
CA2626956A1 (en) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
TWI423972B (zh) 2006-09-28 2014-01-21 Biota Scient Management 治療呼吸系融合細胞病毒感染之多環劑
ES2381234T3 (es) 2007-11-15 2012-05-24 Gilead Sciences, Inc. Inhibidores de la replicación del virus de la inmunodeficiencia humana
CN102124011A (zh) * 2007-11-15 2011-07-13 贝林格尔.英格海姆国际有限公司 人类免疫缺陷病毒复制的抑制剂
MX2010005334A (es) 2007-11-16 2010-05-27 Boehringer Ingelheim Int Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
EP2330902B1 (en) * 2008-07-25 2012-11-14 GlaxoSmithKline LLC Chemical compounds
EP2660239B1 (en) 2008-07-25 2016-11-23 VIIV Healthcare Company Chemical compounds as synthetic intermediates
WO2010011812A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
KR101678563B1 (ko) 2008-12-11 2016-11-22 비이브 헬쓰케어 컴퍼니 카르바모일피리돈 ｈｉｖ 인테그라제 억제제를 위한 제조방법 및 중간체
CA2744019C (en) 2008-12-11 2017-03-14 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
AU2014277831C1 (en) * 2008-12-11 2022-10-06 Shionogi & Co. Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
EP2370419B1 (en) * 2008-12-11 2017-09-27 Shionogi&Co., Ltd. Maltol ether processes and intermediates
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
RS57244B1 (sr) 2009-06-15 2018-07-31 Shionogi & Co Supstituisani policiklički derivati karbamoilpiridona
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
WO2011045330A1 (en) 2009-10-13 2011-04-21 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
AU2014202404C1 (en) * 2010-01-27 2022-06-23 Viiv Healthcare Company Antiviral therapy
SI2932970T1 (en) * 2010-01-27 2018-07-31 Viiv Healthcare Company Antiviral therapy
AU2014202406C1 (en) * 2010-01-27 2019-03-07 Viiv Healthcare Company Antiviral therapy
TWI508968B (zh) 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
MX2012009869A (es) * 2010-02-26 2012-09-12 Japan Tobacco Inc Derivado de 1, 3,4, 8-tetrahidro-2h-pirido[1, 2-a]pirazina y sus uso como inhibidor de la integrasa del vih.
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
CN102958935B (zh) 2010-04-02 2015-12-09 爱尔兰詹森科学公司 大环整合酶抑制剂
WO2011129095A1 (ja) * 2010-04-12 2011-10-20 塩野義製薬株式会社 インテグラーゼ阻害活性を有するピリドン誘導体
US9073941B2 (en) 2010-06-28 2015-07-07 Academia Sinica Compounds and methods for treating tuberculosis infection
EP2602260B1 (en) 2010-08-05 2016-09-28 Shionogi&Co., Ltd. Process for preparing compound having hiv integrase inhibitory activity
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
HUE039859T2 (hu) * 2010-09-24 2019-02-28 Shionogi & Co Helyettesített policiklusos karbamoil-piridon-származék prodrug
US8796303B2 (en) 2010-11-26 2014-08-05 Biota Scientific Management Pty Ltd. Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2013038407A1 (en) 2011-09-14 2013-03-21 Mapi Pharma Ltd. Amorphous form of dolutegravir
US9200009B2 (en) 2011-10-12 2015-12-01 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
CA3142817A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
BR112015014714B1 (pt) 2012-12-21 2018-12-26 Gilead Sciences, Inc. compostos carbamoilpiridona policíclicos, composição farmacêutica que os compreende e seu uso farmacêutico
WO2014104279A1 (ja) * 2012-12-27 2014-07-03 日本たばこ産業株式会社 置換されたスピロピリド［１，２－ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての医薬用途
EP2767272A1 (en) 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
US9480655B2 (en) 2013-02-18 2016-11-01 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
US9573965B2 (en) 2013-02-19 2017-02-21 Aurobindo Pharma Ltd Process for the preparation of Dolutegravir
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014150258A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA037091B1 (ru) 2013-03-15 2021-02-04 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA034922B1 (ru) 2013-03-15 2020-04-07 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
EP2986291B1 (en) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
EP3008044B1 (en) * 2013-06-13 2018-11-21 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2015001572A2 (en) * 2013-07-04 2015-01-08 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
NO2865735T3 (enExample) * 2013-07-12 2018-07-21
AU2014286993B2 (en) * 2013-07-12 2018-10-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections
US9856270B2 (en) 2013-07-17 2018-01-02 Ratiopharm Gmbh Dolutegravir salts
WO2015019310A1 (en) 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof
WO2015039348A1 (en) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
EA030695B1 (ru) * 2013-09-27 2018-09-28 Мерк Шарп И Доум Корп. Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015089847A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015092752A1 (en) 2013-12-20 2015-06-25 Mylan Laboratories Ltd. Novel crystalline form of dolutegravir sodium
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2015110897A2 (en) * 2014-01-21 2015-07-30 Laurus Labs Private Limited Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
KR102345380B1 (ko) 2014-02-07 2021-12-29 글로벌 블러드 테라퓨틱스, 인크. 2-하이드록시-6-((2-(1-이소프로필-1h-피라졸-5-일)피리딘-3-일)메톡시)벤즈알데하이드의 유리 염기의 결정성 다형체
CN107056813B (zh) * 2014-03-19 2019-07-30 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
WO2015140569A1 (en) 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
WO2015177537A1 (en) * 2014-05-20 2015-11-26 Cipla Limited Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof
TWI744723B (zh) * 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (enExample) * 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
JPWO2016027879A1 (ja) * 2014-08-22 2017-06-01 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
US11311545B2 (en) 2014-10-09 2022-04-26 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016102078A1 (en) 2014-12-24 2016-06-30 Ratiopharm Gmbh Solid state forms of dolutegravir sodium
EP3045461A1 (en) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
KR20170113650A (ko) 2015-02-06 2017-10-12 밀란 래버러토리스 리미티드 돌루테그라비어의 제조 방법
CZ201599A3 (cs) 2015-02-13 2016-08-24 Zentiva, K.S. Pevné formy solí dolutegraviru a způsob jejich přípravy
EP3285582B1 (en) * 2015-03-26 2020-11-11 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
TR201905009T4 (tr) * 2015-04-02 2019-05-21 Gilead Sciences Inc Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
RS61381B1 (sr) * 2015-04-28 2021-02-26 Shionogi & Co Derivat policikličnog piridona protiv gripa i njegov prolek
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
CZ2015537A3 (cs) 2015-08-04 2017-02-15 Zentiva, K.S. Pevné formy amorfního dolutegraviru
EP3337479B1 (en) 2015-08-19 2023-12-13 Laurus Labs Limited Novel polymorphs of dolutegravir and salts thereof
PE20181207A1 (es) 2015-11-09 2018-07-23 Gilead Sciences Inc Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
EP3377066B1 (en) 2015-11-17 2021-04-07 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
SI3383392T1 (sl) 2015-12-04 2025-10-30 Global Blood Therapeutics, Inc. Režimi odmerjanja za 2-hidroksi-6-((2-(1-izopropil-1h-pirazol-5-il)piridin-3-il)metoksi)benzaldehid
EP3389380B1 (en) 2015-12-15 2021-07-21 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
ES2742249T3 (es) 2015-12-21 2020-02-13 Lupin Ltd Proceso para la preparación de inhibidores de la integrasa de VIH
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
EP4527463A3 (en) * 2016-06-23 2025-06-25 VIIV Healthcare Company Compositions and methods for the delivery of therapeutics
EP3496718A4 (en) 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
US20190175511A1 (en) 2016-08-08 2019-06-13 Hetero Labs Limited A Multi-Class Anti-Retroviral Composition
US11091483B2 (en) * 2016-08-12 2021-08-17 Madera Therapeutics, LLC Protein kinase regulators
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
US20190216725A1 (en) * 2016-09-21 2019-07-18 Merck Shapr & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
CA3042314A1 (en) 2016-12-02 2018-06-07 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
WO2018140368A1 (en) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
EP3363802B1 (en) 2017-02-16 2019-11-20 Sandoz AG Crystalline form of cabotegravir sodium
EP3583107B1 (en) * 2017-02-16 2020-11-18 Sandoz AG Crystalline form of cabotegravir sodium
JP2020527570A (ja) * 2017-07-18 2020-09-10 ヴィーブ ヘルスケア カンパニー 組み合わせ薬物療法
CN111107850A (zh) 2017-07-21 2020-05-05 Viiv保健公司 用于治疗hib感染和aids的方案
WO2019048808A1 (en) 2017-09-07 2019-03-14 Cipla Limited NOVEL POLYMORPHS OF DOLUTÉGRAVIR SODIQUE
SG11202002789XA (en) 2017-10-06 2020-04-29 Shionogi & Co Stereoselective process for preparing substituted polycyclic pyridone derivatives
CA3126348A1 (en) 2018-01-12 2020-07-18 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2019159199A1 (en) 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
CA3132832A1 (en) 2018-04-09 2019-10-17 Howard E. Gendelman Antiviral prodrugs and formulations thereof
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
MD3805220T2 (ro) 2018-05-31 2024-10-31 Shionogi & Co Derivat policiclic de carbamoilpiridonă
WO2019230857A1 (ja) 2018-05-31 2019-12-05 塩野義製薬株式会社 多環性ピリドン誘導体
TWI820141B (zh) * 2018-05-31 2023-11-01 日商鹽野義製藥股份有限公司 衍生物
WO2020012408A2 (en) 2018-07-12 2020-01-16 Laurus Labs Limited A process for purification of protected polycyclic carbamoylpyridone derivatives
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
EP3870174B1 (en) 2018-10-22 2023-11-01 Board of Regents of the University of Nebraska Antiviral prodrugs and nanoformulations thereof
WO2020112931A1 (en) 2018-11-29 2020-06-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
AU2020245350B2 (en) 2019-03-22 2023-04-20 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
RU2717101C1 (ru) * 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
EP4066839A4 (en) 2019-11-28 2023-12-27 Shionogi & Co., Ltd PROPHYLACTIC AND THERAPEUTIC MEDICINAL PRODUCT FOR HIV INFECTIOUS DISEASES, CHARACTERIZED BY CONTAINING THE COMBINATION OF INTEGRAS INHIBITORS AND ANTI-HIV AGENTS
KR20220112771A (ko) 2019-12-09 2022-08-11 비이브 헬쓰케어 컴퍼니 카보테그라비르를 포함하는 제약 조성물
BR112022015771A2 (pt) 2020-02-24 2022-10-11 Gilead Sciences Inc Compostos tetracíclicos para tratar a infecção por hiv
WO2025068743A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
EP4208169A1 (en) 2020-09-01 2023-07-12 VIIV Healthcare Company Combination of cabotegravir and levonorgestrel
KR20230079137A (ko) 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
US20250296988A1 (en) 2020-12-07 2025-09-25 Viiv Healthcare Company Combination therapy
ES2968058T3 (es) 2021-01-19 2024-05-07 Gilead Sciences Inc Compuestos de piridotriazina sustituidos y usos de los mismos
WO2022253294A1 (zh) 2021-06-03 2022-12-08 江苏恒瑞医药股份有限公司 具有整合酶抑制活性的吡啶酮化合物及其药用用途
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
WO2023102374A1 (en) 2021-12-03 2023-06-08 Viiv Healthcase Company Process of synthesizing (r)-3-aminobutan-1-ol
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
AU2024209826A1 (en) * 2023-01-18 2025-07-10 Ascletis BioScience Co., Ltd Integrase inhibitor and use thereof
TW202529766A (zh) 2023-09-27 2025-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 3)有限公司 醫藥組合物
WO2025128498A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Pharmaceutical compositions
WO2025128496A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Crystalline form
WO2025181723A1 (en) 2024-03-01 2025-09-04 ViiV Healthcare UK (No.3) Limited Dosing regimen

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959316A (en) * 1972-03-13 1976-05-25 Snam Progetti S.P.A. Procedure for propylene oxide synthesis
JPH0296506A (ja) 1988-09-30 1990-04-09 Daicel Chem Ind Ltd 除草剤組成物
JP2533796B2 (ja) 1988-10-18 1996-09-11 ダイセル化学工業株式会社 ５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2551472B2 (ja) * 1988-10-18 1996-11-06 ダイセル化学工業株式会社 ５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
DE69831506T2 (de) 1997-12-22 2006-06-29 Pharmacia & Upjohn Co. Llc, Kalamazoo 4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe
US20040039060A1 (en) † 2000-06-14 2004-02-26 Ryuichi Kiyama Inhibitor for enzyme having two divalent metal ions as active centers
US6580562B2 (en) 2000-07-24 2003-06-17 Yazaki Corporation On-vehicle display unit
US6384263B1 (en) 2000-08-04 2002-05-07 E. I. Du Pont De Nemours And Company Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
ES2287170T3 (es) 2000-10-12 2007-12-16 MERCK & CO., INC. Aza- y poliaza-naftalenil-carboxamidas utilies como inhibidores de la vih integrasa.
JP2003032772A (ja) 2001-07-12 2003-01-31 Foster Electric Co Ltd 耳掛け式イヤホン
ATE530520T1 (de) 2001-08-10 2011-11-15 Shionogi & Co Antivirales mittel
HU230248B1 (hu) 2001-10-26 2015-11-30 Msd Italia S.R.L. N-szubsztituált hidroxipirimidinon-karboxamid HIV-integráz inhibitorok
DK1441734T3 (da) 2001-10-26 2007-06-11 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carboxamid-inhibitorer a HIV-integrase
CA2472372C (en) 2002-01-17 2010-08-17 Melissa Egbertson Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
WO2004004657A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Hiv integrase inhibitors
JP3908248B2 (ja) 2002-08-13 2007-04-25 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有するヘテロ環化合物
CA2498111A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
WO2004058756A1 (en) 2002-12-27 2004-07-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
US6960680B2 (en) 2003-01-08 2005-11-01 Rhodia Chirex, Inc. Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
WO2004101512A2 (en) 2003-05-13 2004-11-25 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
AU2003273190A1 (en) * 2003-08-12 2005-02-25 Rachel Beijer Scheduled message service
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4530642B2 (ja) 2003-10-31 2010-08-25 オリンパス株式会社 内視鏡装置
BRPI0507628A (pt) 2004-02-11 2007-07-03 Smithkline Beecham Corp composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
CN1930161A (zh) 2004-03-09 2007-03-14 P·安杰莱蒂分子生物学研究所 Hiv整合酶抑制剂
EP1725102A4 (en) 2004-03-09 2009-04-29 Merck & Co Inc HIV integrase
US7538112B2 (en) 2004-05-07 2009-05-26 Merck & Co., Inc. HIV integrase inhibitors
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
US7858788B2 (en) * 2005-02-21 2010-12-28 Shionogi & Co., Ltd. Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
US7981879B2 (en) * 2005-03-31 2011-07-19 Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. HIV integrase inhibitors
SI3372281T1 (sl) * 2005-04-28 2021-11-30 Viiv Healthcare Company Policiklični karbamoilpiridonski derivati, ki imajo aktivnost inhibitorja HIV integraze
JP2005312076A (ja) 2005-05-26 2005-11-04 Olympus Corp 電子撮像装置
US20080214527A1 (en) 2005-08-04 2008-09-04 Takashi Kawasuji Hiv Integrase Inhibitors
CA2626956A1 (en) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Also Published As

Publication number Publication date
HUS2100022I1 (hu) 2021-07-28
IL186555A (en) 2016-10-31
NO2021018I1 (no) 2021-05-10
SI3187225T1 (sl) 2022-04-29
HUE044978T2 (hu) 2019-11-28
CY2014024I2 (el) 2025-05-09
US20170209454A1 (en) 2017-07-27
PT3045206T (pt) 2018-07-05
AU2006239177B8 (en) 2012-02-16
HUE056603T2 (hu) 2022-02-28
FIC20210017I1 (fi) 2021-06-10
EP3045206B2 (en) 2023-02-15
IL186555A0 (en) 2008-01-20
PT3284520T (pt) 2019-09-10
LTPA2014021I1 (lt) 2014-07-25
CA2606282A1 (en) 2006-11-02
ES2567197T3 (es) 2016-04-20
MX312216B (en) 2013-08-12
ES2743531T3 (es) 2020-02-19
ES2437268T3 (es) 2014-01-09
EA014162B1 (ru) 2010-10-29
DK3372281T3 (da) 2021-09-27
US8778943B2 (en) 2014-07-15
WO2006116764A1 (en) 2006-11-02
IL225206A (en) 2017-11-30
DK3284520T3 (da) 2019-09-16
US20190152990A1 (en) 2019-05-23
IL225207A (en) 2017-11-30
NO2023042I1 (no) 2023-11-08
MX2007013351A (es) 2008-01-21
US20240279238A1 (en) 2024-08-22
KR20140097438A (ko) 2014-08-06
TWI378931B (en) 2012-12-11
KR101580310B1 (ko) 2016-01-04
US20190284208A1 (en) 2019-09-19
US20170253616A1 (en) 2017-09-07
EP2527007B1 (en) 2016-03-30
NL301109I1 (nl) 2021-09-15
BE2021C519I2 (enExample) 2025-12-10
NO2017010I2 (no) 2017-03-27
US20140200209A1 (en) 2014-07-17
EP3187225A1 (en) 2017-07-05
EP1874117B1 (en) 2013-08-28
EP3045206A1 (en) 2016-07-20
PL1874117T3 (pl) 2014-01-31
JP2008540343A (ja) 2008-11-20
EP1874117A4 (en) 2009-12-30
AU2006239177A1 (en) 2006-11-02
EP1874117A1 (en) 2008-01-09
SI2465580T1 (sl) 2014-04-30
US9051337B2 (en) 2015-06-09
NL300676I2 (enExample) 2016-10-11
EP3045206B1 (en) 2018-03-28
KR20080009733A (ko) 2008-01-29
LT3372281T (lt) 2021-12-10
CY2014024I1 (el) 2015-12-09
US20090318421A1 (en) 2009-12-24
US8129385B2 (en) 2012-03-06
EP2465580B1 (en) 2013-12-18
PL3372281T3 (pl) 2021-12-27
CY1124601T1 (el) 2022-07-22
BRPI0610030A2 (pt) 2011-10-11
HK1107227A1 (en) 2008-04-03
NO339525B1 (no) 2016-12-27
DK1874117T3 (da) 2013-09-23
IL215788A0 (en) 2011-12-29
AU2006239177B2 (en) 2011-10-20
US20160304535A1 (en) 2016-10-20
LT3045206T (lt) 2018-06-11
FR14C0041I2 (fr) 2015-11-13
CY1120345T1 (el) 2019-07-10
EP3284519A1 (en) 2018-02-21
NZ562339A (en) 2011-01-28
ES2667868T3 (es) 2018-05-14
EP3372281B1 (en) 2021-07-07
LU92446I2 (fr) 2015-10-29
EA200702080A1 (ru) 2008-04-28
DK2465580T3 (en) 2014-03-10
EP3372281A1 (en) 2018-09-12
NO20161315A1 (no) 2007-11-22
VN34404A1 (en) 2013-07-25
US20170224694A1 (en) 2017-08-10
LTPA2021512I1 (enExample) 2021-07-12
HUS2100023I1 (hu) 2021-07-28
US20170260203A1 (en) 2017-09-14
KR101504998B1 (ko) 2015-03-23
HK1251191A1 (en) 2019-01-25
HK1172282A1 (en) 2013-04-19
PT1874117E (pt) 2013-10-17
US20170029438A1 (en) 2017-02-02
EP2465580A1 (en) 2012-06-20
US11267823B2 (en) 2022-03-08
EP3284520B1 (en) 2019-06-05
KR101363875B1 (ko) 2014-02-21
CY2021016I2 (el) 2021-12-31
EP3284520A1 (en) 2018-02-21
CY2021016I1 (el) 2021-10-15
SI3284520T1 (sl) 2019-10-30
US20170224695A1 (en) 2017-08-10
EP3284519A8 (en) 2018-04-18
KR20130133061A (ko) 2013-12-05
PT2465580E (pt) 2014-02-25
NO20075165L (no) 2007-11-22
CY1115151T1 (el) 2015-12-09
US10927129B2 (en) 2021-02-23
US20170369509A1 (en) 2017-12-28
SI1874117T1 (sl) 2014-01-31
ES2667868T5 (es) 2023-06-01
EP1874117B8 (en) 2014-03-12
LT3284520T (lt) 2019-09-25
EP3187226A1 (en) 2017-07-05
US20160207939A1 (en) 2016-07-21
KR20160003889A (ko) 2016-01-11
US20160137666A1 (en) 2016-05-19
US20150232479A1 (en) 2015-08-20
LTC1874117I2 (lt) 2025-03-25
NO2017010I1 (no) 2017-03-27
JP2009079058A (ja) 2009-04-16
US20170267693A1 (en) 2017-09-21
ES2892304T3 (es) 2022-02-03
ES2446324T3 (es) 2014-03-07
DK3045206T3 (en) 2018-05-22
FR14C0041I1 (enExample) 2014-06-27
DK3187225T3 (da) 2022-02-28
SI3045206T1 (en) 2018-07-31
BRPI0610030B1 (pt) 2020-09-15
HUS1400039I1 (hu) 2016-08-29
HUE037795T2 (hu) 2018-09-28
PL3284520T3 (pl) 2020-01-31
HK1249742A1 (en) 2018-11-09
NO340111B1 (no) 2017-03-13
US20170145033A1 (en) 2017-05-25
PL3045206T3 (pl) 2018-08-31
LUC00210I2 (enExample) 2022-10-07
US20120115875A1 (en) 2012-05-10
PL2465580T3 (pl) 2014-05-30
EP2527007A1 (en) 2012-11-28
CY1122052T1 (el) 2020-10-14
US20130172559A1 (en) 2013-07-04
US20200339598A1 (en) 2020-10-29
PT3372281T (pt) 2021-10-14
SI3372281T1 (sl) 2021-11-30
LTC2465580I2 (enExample) 2022-10-10
MA29460B1 (fr) 2008-05-02
TW200716635A (en) 2007-05-01
US9273065B2 (en) 2016-03-01
CA2606282C (en) 2016-04-26
ES2906792T3 (es) 2022-04-20
EP3187225B1 (en) 2022-01-05
CY1116331T1 (el) 2017-02-08
KR101848819B1 (ko) 2018-04-16
NL301109I2 (nl) 2021-09-15
US20220213121A1 (en) 2022-07-07
JP4295353B2 (ja) 2009-07-15
US8410103B2 (en) 2013-04-02
MX302718B (es) 2012-08-27

Similar Documents

Publication Publication Date Title
BRPI0610030B8 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0408767A (pt) inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv
BRPI0714553B8 (pt) derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso
ATE526341T1 (de) Makrozyklische verbindungen als antivirale mittel
UY28578A1 (es) Derivados de amida
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
BR0315580A (pt) Derivados de metileno uréia
BR0306208A (pt) Compostos de dibenzilamina e seu uso farmacêutico
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
BR112013026345A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
BRPI0512075A (pt) composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença
BRPI0414514A (pt) uso de um composto, composto, e, composições farmacêuticas
BRPI0407591A (pt) inibidores de transcriptase reversa de não-nucleosìdeo
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
AR044177A1 (es) Proceso para la preparacion de trans-isomeros de derivados de la difenilazetidinona
BRPI0407695A (pt) compostos, processo para a preparação de um composto, composições farmacêuticas que compreendem o composto, utilização dos compostos e processo de tratamento para diabetes do tipo 2
BR112021018238A2 (pt) Derivados de azolopiridina macrocíclicos como moduladores de eed e prc2
BRPI0310032B8 (pt) derivados de benzoxazina, seus usos e seus processos de produção, e composição farmacêutica
UA96568C2 (en) Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
AR059032A1 (es) Combinacion de derivados de triazina y sensibilizadores de insulina
BRPI0513858B8 (pt) compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
BR0109900A (pt) Derivados de pirolidina farmaceuticamente ativos, uso de derivados de pirolidina, composição farmacêutica e processo para preparação de um derivado de pirolidina
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
BR112021011325A2 (pt) Derivados de rapamicina
ECSP066947A (es) Combinaciones farmacológicas que contienen benzoxazina para el tratamiento de enfermedades de las vías respiratorias

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SHIONOGI AND CO., LTD. (JP) , GLAXOSMITHKLINE LLC

B25A Requested transfer of rights approved

Owner name: SHIONOGI AND CO., LTD. (JP) , VIIV HEALTHCARE COMP

B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52402.009089/2020-01 TRIBUNAL REGIONAL FEDERAL DA 2A REGIAO PROCESSO: NO 5011530-20.2020.4.02.0000 AGRAVANTE: BLANVER FARMOQUIMICA E FARMACEUTICA S.A. AGRAVADO: SHIONOGI AND CO LTD., INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI, DIRETORA DE PATENTES, PROGRAMA DE COMPUTADOR E TOPOGRAFIAS DE CIRCUITOS INTEGRADOS, INPI-INSTITUTO NACIONAL DE PROPRIEDADE INDUSTRIAL - RIO DE JANEIRO E VIIV HEALTHCARE COMPANY DECISAO: DEFIRO A TUTELA DE URGENCIA PARA SUSPENDER OS EFEITOS DO ATO DE CONCESSAO DA PATENTE PI 0610030-9, ATE O JULGAMENTO DO MERITO DO PRESENTE AGRAVO.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.008950/2020-13 ORIGEM: 31A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO: O 5054471-08.2020.4.02.5101/RJ SUBJUDICE COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: BLANVER FARMOQUIMICA E FARMACEUTICA S.A. REU(S): PESQUISADORA DA DIRETORIA DEPATENTES ? DIRPA, CAROLINA SOARES BEMVINDO HASHIMOTO E A DIRETORA DE PATENTES DOINSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI, LIANE ELIZABETH CALDEIRA LAGE

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI NO 52402.012072/2020-22 NUP: 00408.070481/2020-90 (REF. 5015433-63.2020.4.02.0000) INTERESSADOS: BLANVER FARMOQUIMICA E FARMACEUTICA S.A. E OUTROSDECISAO: ISSO POSTO, DEFIRO A TUTELA DE URGENCIA PARA SUSPENDER A EFICACIA DO ATO DE CONCESSAO DA PATENTE PI0610030-9, ATE O JULGAMENTO DO MERITO DA APELACAO INTERPOSTA NOS AUTOS DO MANDADO DE SEGURANCA NO 5054471-08.2020.4.02.5101.

B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTE DA NULIDADE: ASSOCIACAO BRASILEIRA INTERDISCIPLINAR DE AIDS - 870210006696 - 19/01/2021

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.012072/2020-22 NUP: 00408.070481/2020-90 (REF. 5015433-63.2020.4.02.0000) INTERESSADOS: BLANVER FARMOQUIMICA E FARMACEUTICA S.A. E OUTROS DECISAO:O TRF2 NEGOU PROVIMENTO A APELACAO INTERPOSTA, MANTENDO HIGIDA A PATENTE PI 0610030-9. DIANTE DISSO, DEVE SER ANOTADA A REVOGACAO DA ANTECIPACAO DE TUTELA QUE HAVIA SUSPENDIDO OS EFEITOS DA PATENTE, POIS O ATO ADMINISTRATIVO DE CONCESSAO DA PATENTE FOI DECLARADO VALIDO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO (PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/04/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO )

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.000957/2022-41 ORIGEM: JUIZO SUBSTITUTO DA 13A VF DO RIO DE JANEIRO (TRF2) PROCESSO NO: 5005427-49.2022.4.02.5101 NULIDADE DE ATO ADMINISTRATIVO COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: BLANVER FARMOQUIMICA E FARMACEUTICA S.A. REU(S): SHIONOGI AND CO LTD. E VIIV HEALTHCARE COMPANY E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.000957/2022-41 NUP: 00408.004133/2022-96 (REF. 5005427-49.2022.4.02.5101) AUTOR: BLANVER FARMOQUIMICA E FARMACEUTICA S.A. REU: ASSOCIACAO BRASILEIRA INTERDISCIPLINAR DE AIDS REU: VIIV HEALTHCARE COMPANY REU: INPI-INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL REU: AGENCIA NACIONAL DE VIGILANCIA SANITARIA - ANVISA REU: SHIONOGI AND CO LTD. DECISAO: COMPROVADO O DEPOSITO DA CAUCAO DESCRITO NO ITEM PRECEDENTE, E PELAS RAZOES AMPLAMENTE EXPOSTAS NOS ITENS IMEDIATAMENTE ANTERIORES, FICA DEFERIDA A TUTELA PROVISORIA DE URGENCIA, PARA SUSPENDER OS EFEITOS DA PATENTE PI0610030-9, EXCLUSIVAMENTE EM RELACAO A EMPRESA AUTORA BLANVER, TODO O SEU GRUPO ECONOMICO E SOC

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.007297/2022-29 TRIBUNAL REGIONAL FEDERAL DA 2A REGIAO AGRAVO DE INSTRUMENTO NO 5008464-61.2022.4.02.0000/RJ AGRAVANTE: VIIV HEALTHCARE COMPANY AGRAVANTE: SHIONOGI AND CO LTD. AGRAVADO: BLANVER FARMOQUIMICA E FARMACEUTICA S.A. AGRAVADO: INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL SENTENCA: EM FACE DO EXPOSTO, DEFIRO O EFEITO SUSPENSIVO, PARA SUSPENDER A DECISAO AGRAVADA, ATE ULTERIOR DECISAO DO TRIBUNAL.

B19A Notification of judicial decision: notification of judicial decision

Free format text: NOTIFICACAO DE DECISAO JUDICIAL (PROCESSO INPI NO 52402.014827/2023-76) TUTELA ANTECIPADA ANTECEDENTE NO161/RJ (2023/0462102-5) TRIBUNAL REGIONAL FEDERAL DA 2A REGIAO REQUERENTE: BLANVER FARMOQUIMICA E FARMACEUTICA S.A. REQUERIDO: VIIV HEALTHCARE COMPANY; SHIONOGI AND CO LTD. E INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL SENTENCA: "ANTE AO EXPOSTO, INDEFIRO O EFEITO SUSPENSIVO REQUERIDO."